SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 57 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $392 | -30.6% | 27,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $565 | -64.1% | 27,000 | -63.9% | 0.00% | 0.0% |
| Q1 2023 | $1,575 | +148.8% | 74,700 | +200.0% | 0.00% | -33.3% |
| Q4 2022 | $633 | -99.9% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $598,000 | +24.8% | 24,900 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $479,000 | +17.4% | 24,900 | +6.0% | 0.00% | +100.0% |
| Q1 2022 | $408,000 | +3038.5% | 23,500 | +1466.7% | 0.00% | – |
| Q4 2017 | $13,000 | -23.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2017 | $17,000 | -15.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2017 | $20,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $20,000 | +100.0% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $10,000 | -54.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $22,000 | +46.7% | 1,500 | -6.2% | 0.00% | – |
| Q2 2016 | $15,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |